Disseminated Geosmithia argillacea Infection in a Patient with Ph-Positive Acute Lymphoblastic Leukemia. Case Report and Literature Review
暂无分享,去创建一个
[1] L. Pagano,et al. Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons , 2018, Expert review of anti-infective therapy.
[2] Sudhir Kumar,et al. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. , 2016, Molecular biology and evolution.
[3] V. Pavone,et al. Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) , 2015, Haematologica.
[4] Kyung Sun Park,et al. Isolation and Identification of Geosmithia argillacea from a Fungal Ball in the Lung of a Tuberculosis Patient , 2013, Annals of laboratory medicine.
[5] M. Asslaber,et al. Disseminated Geosmithia argillacea infection in a patient with gastrointestinal GvHD , 2012, Bone Marrow Transplantation.
[6] S. Holland,et al. Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] O. Lortholary,et al. Emergence of Disseminated Infections Due to Geosmithia argillacea in Patients with Chronic Granulomatous Disease Receiving Long-Term Azole Antifungal Prophylaxis , 2011, Journal of Clinical Microbiology.
[8] L. Mély,et al. Geosmithia argillacea: an Emerging Pathogen in Patients with Cystic Fibrosis , 2010, Journal of Clinical Microbiology.
[9] J. Houbraken,et al. Isolation of the Fungus Geosmithia argillacea in Sputum of People with Cystic Fibrosis , 2010, Journal of Clinical Microbiology.
[10] B. Wickes,et al. Disseminated Geosmithia argillacea infection in a German shepherd dog. , 2009, Medical mycology.
[11] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[12] M. Falagas,et al. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta‐analysis of randomised‐controlled trials , 2005, British journal of haematology.
[13] D. Kontoyiannis,et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] O. Cornely,et al. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. , 2003, Blood.
[15] S J Lin,et al. Aspergillosis case-fatality rate: systematic review of the literature. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] B. Lebeau,et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] E. Anaissie,et al. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. , 1997, Blood.
[18] N. L. Glass,et al. Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes , 1995, Applied and environmental microbiology.
[19] L. Pagano,et al. Design and Methods , 2022 .